Background
Material and methods
FDA register number | Compound |
Mechanism
| Cohort (years) | Sample size | Outcomes measured (OM) | Phase/sponsor | Results/publications | |
---|---|---|---|---|---|---|---|---|
Primary1
| Secondary2
| |||||||
14/22, 64%
| ||||||||
NCT00788073 | Arbaclofen (STX209) |
GABA-B agonist | 6–50 | 63 | ABC-C_I | ABC-CFX, CGI-S, CGI-I, Vineland-II, SRS, RBANS, SB5, PPVT | II/Seaside | OM:1 not met, 2↓ABC-CFX-SA [112] |
NCT01282268 | Arbaclofen |
GABA-B agonist
| 12–50 | 125 | ABC-CFX_SA | CGI-S, CGI-I, Vineland-II, ADHD-RS, SB5, PSI, CSHQ | III/Seaside | OM:1 not met [46] |
NCT01325220 | Arbaclofen |
GABA-B agonist
| 5–11 | 172 | ABC-CFX_SA | CGI-S, CGI-I, Vineland-II, ADHD-RS, SB5, PSI, CSHQ | III/Seaside | |
NCT01725152 | Ganaxolone |
GABA-A agonist
| 6–17 | 60 | CGI-I | ABC-CFX, ADAMS, PPI, KiTAP, ERP, ET, SNAP-IV, PARS | II/Marinus | Pending |
NCT02126995 | Metadoxine |
GABA transporter
| 14–50 | 62 | ADHD-RS | ABC-CFX, CGI-S, CGI-I, Vineland-II, SRS, KiTAP, ERP, ET, PARS | II/Alcobra | |
NCT00718341 | Mavoglurant (AFQ056) |
mGluR5 antagonist
| 18–35 | 30 | ABC-C_T | ABC-CFX, CGI-S, CGI-I, SRS, KiTAP, ET, VAS, RBANS.. | II/Novartis | OM:1 not met,2 ↓ABC-C_T (n=7 FM) [261] |
NCT01253629 | Mavoglurant |
mGluR5 antagonist
| 18–45 | 175 | ABC-C_T | ABC-C, CGI-S, CGI-I, SRS, KiTAP | IIb/Novartis | OM:1 & 2 not met, tolerated well [9] |
NCT01357239 | Mavoglurant |
mGluR5 antagonist
| 12–17 | 139 | ABC-C_T | ABC-C, CGI-S, CGI-I, SRS, KiTAP | IIb/Novartis | OM:1 & 2 not met, tolerated well [9] |
NCT01015430 | Basimglurant (RO4917523) |
mGluR5 antagonist
| 18–50 | 40 | Safety, PK | ABC-C, ADAMS, CGI-S, CGI-I, KiTAP, ET, VAS, RBANS | IIa/Roche | Not in public domain |
NCT01517698 | Basimglurant |
mGluR5 antagonist
| 14–40 | 185 | ADAMS_T | ABC-C, ADAMS, CGI-S, CGI-I, WISC-IV, CBI-M | IIb/Roche | Not in public domain |
NCT01750957 | Basimglurant |
mGluR5 antagonist
| 5–13 | 180 | Safety | PK, ABC-C, ADAMS, CGI-S, CGI-I, WISC-IV, CBI-M | IIb/Roche | Not in public domain |
NCT01911455 | Acamprosate |
GABA/Glutamate
| 5–23 | 48 | ABC-C_SW | CGI-S, CGI-I, VAS, ABC, PARS, ADAMS, CSQ, ELS, SRS | II/III Cinn Child | Pending |
NCT01894958 | Trofinetide |
IGF-1 analog
| 14–40 | 70 | Safety | CGI-S, CGI-I, ABC-CFX, SRS, FXS scale, VAS-P/C, KiTAP | II/Neuren | OM: 1Tolerated well, 2-several improved [63] |
NCT00054730 | CX516 |
Ampakine
| 18+ | 49 | Memory | CGI-I, multiple Z scores, SNAP-IV | II/Cortex | OM: 1 Tolerated well,2↑CGI-I in a subset [40] |
NCT01053156 | Minocycline | MMP-9 | 3–16 | 66 | CGI-I,VAS | VAS-mb, ABC-C, Vineland-II, EVT-2 | II/UC Davis | OM:1 ↑CGI-I, 2↑VAS, ↓MMP-9; [87] |
NCT01474746 | Sertraline | SSRI | 2–6 | 30 | CGI-I,VAS | Vineland-II, PSI-4, PLS-5, MSEL | II/UC Davis | OM:1↑CGI-I (46%),2 ↑VAS [262] |
NCT01120626 | Donepezil | Cholinergic drug | 12–29 | 45 | ABC-C_T/CNT | MRS, WM tests, CARS | II/Stanford | Pending |
NCT01254945 | Oxytocin | Brain peptide | 13–28 | 8 | Eye gaze | HR, RSA, HRV, cortisol | Ib/Stanford | |
NCT01329770 | Vitamins C & E | Antioxidants | 6–18 | 30 | DBC, WISC | Tolerability | II/Imabis | Pending [264] |
N/A | Melatonin | Hormone | 2–15 | 15 | Sleep times | Actiwatch | II/UC Davis | OM:1↑sleep; [265] |
N/A | L-AcCarnitine | Brain energy | 6–13 | 63 | ConnersGI-P | Vineland-Survey, WISC-R | II/TELETHON | OM:1↓HI/I, 2↑Vineland [266] |
N/A | MPH/DAMP | Stimulants | 3–11 | 15 | ConnersAbb | ACTeRS, IQ measures | II/Denver Child | OM:1MPH:↓I, 2↓ACTeRS; [267] |
Results
Cognitive measures
Background
Domain | Outcome measure |
Shorter term
|
Longer term
| Quality of tools |
---|---|---|---|---|
Intellectual quotient | Wechsler_WAIS-IV, WPPSI-IV, WISC-V | Yes | ||
Stanford-Binet 5 | Yes | |||
Multiple cognitive skills | NIH Toolbox Cognitive Battery | Yesa
| Yes | |
Adaptive behavior | ||||
Vineland-II | Yes | |||
ILS | Yes | |||
W-ADL | Yes | + [100] | ||
Memory & Learning | ||||
WJ working memory | Yes | Yes | ||
RBANS | Yes | Yes | ||
SB-5 Block Span | Yes | Yes | ||
Executive function | ||||
KiTAP (4 subtests) | Yes | Yes | ||
WJ auditory attention | Yes | Yes | ||
WJ digits reversed | Yes | Yes | ||
Language | ||||
PPVT-4 | Yes | |||
EVT-2 | Yes | + [68] | ||
CELF-5/P2 | Yes | |||
FMP | Yes | |||
ELS | Yes | Yes | ||
Social cognition | ||||
SRS | Yes | Yes | ||
Eye tracking | Yes | Yes | ||
SPPA | ? | ? | ? [89] | |
Academic achievement | ||||
WJ Achievement III | Yes | |||
WIAT-II | Yes |
Progress and plans in FXS
Potential measures
Conclusions
Behavior and Emotion measures
Subdomain | Outcome measure |
Shorter term
|
Longer term
| Quality of tools |
---|---|---|---|---|
Irritability/aggression | ||||
ABC-C_I | Yes | Yes | ||
ABC-Cfx_I | Yes | Yes | ||
Stereotype/self-injury/aggression | BPI-S | Yes | ||
Variety of behaviors | FXS Rating Scale | Yes | Yes | |
Inattention | Conners/ADHD-RS | Yes | ||
Hyperactivity/impulsivity | Conners/ADHD-RS | Yes | ||
Hyperactivity/impulsivity/inattention | CBCL_ADHD Scale | Yes | ||
Hyperactivity/impulsivity/inattentiona
| SNAP-IV | Yes | ||
Anxiety | ||||
Social withdrawal/anxiety | ABC-C_SW | Yes | Yes | |
Social anxiety | ||||
PARS | Yes | Yes | ||
ADAMS | Yes | Yes | ||
ADAMS Social Avoidance | Yes | Yes | ||
CBCL Withdrawn | Yes | Yes | ||
CBCL’s DSM-Anxiety | Yes | |||
SCARED | Yes | |||
Repulsive/compulsive behavior | RBS-R | Yes | ||
Social reciprocity/avoidance | SRS | Yes | Yes |
Problem behaviors: focus on disruptive behavior domain
Background
Progress and plans in FXS
Potential measures
Conclusions
Attention-deficit hyperactivity disorder (ADHD)-like behaviors
Background
Progress and plans in FXS
Potential measures
Conclusions
Anxiety
Background
Progress and plans in FXS
Potential measures
Conclusions
Autistic behavior
Background
Progress and plans in FXS
Potential measures
Domain | Outcome measure |
Shorter term
|
Longer term
| Quality of tools |
---|---|---|---|---|
Autistic behavior | ||||
ADOS | Yes | Yes | ||
SRS | Yes | |||
CARS | Yes | |||
SCQ | Yes | |||
RBS-R | Yes | |||
Repetitive non-autistic behavior | ||||
RBS-R | Yes | |||
RBQ | Yes | + [189] | ||
BPI-S | Yes |
Conclusions
Repetitive behaviors other than autistic behavior
Background
Progress and plans in FXS
Potential measures
Conclusions
Overall conclusions on Behavior and Emotion measures
Biomarkers and Medical measures
Domains | Potential outcome Measure |
Shorter term
|
Longer term
| Quality of tools |
---|---|---|---|---|
Blood and tissue | ||||
FMR1/FMRP expressiona
|
FMR1 methylation | Yes | Yes | |
FMRP levels | Yes | Yes | ||
Signaling pathway | ||||
ERK activation rate | Yes | Yes | ||
BDNF level | Yes | Yes | ||
APP and metabolites levels | Yes | Yes | ||
MMP activity | Yes | Yes | ||
mTOR activity | Yes | Yes | + [269] | |
S6 Kinase activity | Yes | Yes | + [269] | |
Neurophysiological | ||||
Electroencephalogram | Yes | |||
Event-related potentials | Yes | Yes | ||
Prepulse inhibition (PPI) | Yes | |||
Eye tracking and pupillometry | Yes | |||
Neuroimaging | MRI | |||
sMRI | Yes | Yes | + [235] | |
-vMRI | Yes | Yes | ||
-DWI | Yes | Yes | ||
Functional MRI | ||||
-fMRI | Yes | Yes | ||
-rs-fMRI | Yes | Yes | + [77] | |
-MRS | Yes | Yes | + [270] | |
-pMRI | Yes | Yes | + [234] | |
NIRS | Yes |